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Abstract
Graves’ disease (GD) is the most common cause of paediatric hyperthyroidism.  In children
and adolescents,  the  clinical  GD course  is  different  from that  seen  in  adults,  due to  low
remission rate and high  prevalence of adverse events  related to treatment with antithyroid
drugs (ATDs). Most patients in this group require definitive therapy. As in adults, there are 2
treatment options – thyroid ablation with radioactive iodine (RAI) or surgery with preferred
procedure of total thyroidectomy (TT). The choice of definitive therapy depends on many
important  factors  such  as  the  child’s  age,  effectiveness  of  the  first-line  ATD  treatment,
presence of ATD side effects, presence of large goitre or thyroid nodules, and concomitant
diseases.
The following paper  provides  the current  guidelines  on GD management  in  children  and
compares the efficacy of both definitive treatment methods as well as the acute and long-term
complication rates, which must be taken into account when choosing the optimal therapeutic
option.
Key words: Graves’ disease (GD); antithyroid drugs (ATDs); radioactive iodine (RAI); total
thyroidectomy (TT)
Introduction
Graves’ disease (GD) is an autoimmune endocrinopathy with TSH receptor antibodies (TSH-
R-Ab), which imitate the TSH effect and stimulate thyroid growth and excessive hormone
production. As in adults, GD is a major cause of hyperthyroidism in children and adolescents.
The  paediatric  population  constitutes  only  1–5% of  all  patients  with  GD;  however,  it  is
characterized by some important distinctive features, such as much lower remission rate and
higher prevalence of adverse reactions to antithyroid drugs (ATDs) [1, 2]. The majority of GD
paediatric patients will ultimately require definitive therapy with radioactive iodine (RAI) or
total thyroidectomy (TT). One should realize the specificity of Graves’ disease in children and
adolescents in order to optimize treatment outcomes.
Important features of Graves’ disease in children
Graves’ disease  may  occur  at  any  age  during  childhood  and  has  its  peak  during
adolescence;  it is  much more  frequent  in  girls  than  in  boys.  The incidence  of  childhood
thyrotoxicosis seems to have increased in recent years [1–4]. The frequency of GD is higher
when  associated  with  coexisting  autoimmune  or  genetic  diseases,  e.g.  Down  syndrome,
Turner syndrome, or Di George syndrome, as well as in families with a history of autoimmune
thyroid  disorders.  There  are  also  some  environmental  factors  regarded  as  potentially
associated with increased risk of GD in the paediatric population: iodine excess (mandatory
salt iodination), infectious diseases, selenium status, dioxins, or radiation exposure [5–10].
Clinical thyrotoxicosis in GD children is more severe than in GD adults, with tremor,
palpable  goitre,  weight  loss,  muscle  weakness,  lack  of  energy, sleep  disturbances,  and
irritability. Specific signs such as accelerated growth or increased bone age may be observed.
Some disturbances such as impaired educational outcomes, subtle changes in behaviour, or
anxiety  may  have  been  present  for  years  prior  to  diagnosis.  Some  studies  indicate  that
children and adolescents with GD are at  higher risk of serious behavioural problems, and
anxiety or inattention were the prominent behavioural manifestations both during the active
and  normalized  thyroid  hormone  level  states.  Both  hyperthyroidism  and  hypothyroidism
(because of treatment) may result in educational and social difficulties in young patients, and
this factor must be  taken into account  throughout the whole process of therapeutic decision
making [11].
Graves’ orbitopathy (GO) is quite often seen in this population (38%), especially in
adolescents (11–18 years old, 68.2%), usually mild with proptosis and soft tissue involvement
as the main manifestations [12, 13].
As  in  adults,  there  are  3  treatment  options  for  GD in  children:  antithyroid  drugs
(ATDs),  radioactive iodine (RAI) ablation,  and thyroidectomy.  The first-line treatment for
most children with GD is the use of ATDs, but the outcome of pharmacological treatment in
paediatric GD patients is disappointing, with remission rates not exceeding 25–30% and a
higher prevalence of adverse reactions [14, 15].
Treatment with ATDs
In children with GD treated with ATDs thiamazole (methimazole MMI or carbimazole
CBZ, metabolized to MMI in the liver) is preferred because of its once-daily dosing regimen
and  rapid  thyroid  hormone  normalization  with  fewer  adverse  events  compared  to
propylthiouracil (PTU). PTU is associated with an unacceptable risk of side effects, especially
liver failure.  In the US, when PTU was initially less expensive than MMI and was used –
predominantly in the 1980s, many cases of serious PTU-associated hepatic dysfunction were
reported in paediatric patients.
  Because  safety  of  treatment  is  the  priority,  initial  doses  of  ATDs  in  paediatric
treatment are low and calculated according to the patient’s weight. For mild cases the stated
starting MMI dose is 0.25–0.5 mg/kg/d with an upper limit of 30 mg/d. If predictors of poor
prognosis are present, e.g. large goitre, highly elevated pre-treatment fT4 level or TRAb level,
and  in  severe  cases  with  symptoms of  heart  failure, the  starting  MMI dose  should  be  1
mg/kg/d MMI. Concomitant use of β-blockers is useful for patients with severe symptoms as
an initial treatment aimed at reducing tachycardia.
Majority of ATDs’ adverse events occur within 3 months, so monitoring should be
performed every 2 weeks during this period. The white blood count (WBC) levels of aspartate
aminotransferase  (AST),  alanine  aminotransferase  (ALT),  gamma-glutamyl  transpeptidase
(GGTP), and total bilirubin should be checked.
MMI doses are usually reduced after normalization of serum fT4 and fT3 levels, then
MMI in minimal  dose (2.5–10 mg/d)  is  continued for  at  least  18–24 months  in  order  to
maintain  remission.  The  patient  is  monitored  every  3–4  months,  so  that  normal  thyroid
function can be confirmed. 
The decision to discontinue ATDs is difficult and must be made carefully. Stable TSH
levels, results of TRAb level measurements, or clinical observations can be used to make such
judgments. Paediatric endocrinologists are likely to continue ATD even for years, especially
in younger patients (< 15 years old) with poor remission prognosis or in adolescent patients,
with  the  intention  of  maintaining  stability  in  the  young  person’s  school  life  (entrance
examinations, sport activity, and so on). During adolescence the compliance may also be a
particularly difficult issue.
The remission rate during long-term ATDs therapy varied from 11 to 49%, even when
the time of drug usage was extended to over 2 years [16–18].
 In case of relapse, long-term use of low-dose ATDs (MMI or CBZ) is  a possible
solution.  The advantages of ATD therapy include a lack radioactive iodine exposure and no
surgical procedure fraught with risk of complications. On the other hand, we have permanent
treatment,  frequent control  visits,  unstable  thyroid hormones levels,  and the possibility of
adverse drug reactions. 
The decision about definitive therapy and the choice between RAI and TT depend on
the patient’s age, the effectiveness of first-line ATD treatment, the presence of side effects
from the used  drug,  and certain  clinical  features,  such as  the  presence  of  large goitre  or
thyroid nodules. For some children with chronic comorbidities (especially cardiac failure or
diabetes) the primary definitive therapy of GD could be the best option.
Radioactive iodine therapy (RAI) in children  
Properly  administered  RAI  is  a  safe  and  reliable treatment  for  GD  in  the  paediatric
population, but it is still viewed as controversial by some practitioners.  131I therapy should be
considered in children and adolescents without remission after ATD therapy and in the case of
severe  adverse events due to ATDs, but it  can also be used as the first-line treatment.  A
sufficient amount of  131I should be administered as a single dose, and the goal is to induce
permanent  hypothyroidism. According  to  American  Thyroid  Association  and  American
Association of Clinical Endocrinologists  (ATA/AACE) guidelines, RAI should be avoided in
children younger than 5 years and is acceptable in children aged 5–10 years if less than 10
mCi of 131I is administered. In children older than 10 years of age the activity of 131I should be
more than 150 μCi/g of thyroid tissue. In case of large goitre (50–80 g), higher administered
activities of 131I (200–300 μCi of 131I per gram) may be needed [16, 17].
As in adults, pretreatment with ATDs is useful, with the medication being stopped 3–5 days
before RAI. Restart of MMI after RAI is rare in children because the risk of thyroid storm in
this group is low, and post-RAI treatment with methimazole is associated with an increased
failure rate of RAI therapy [19–21].
At some centres a fixed dose of about 15 mCi  131I is administered to all children, whereas
others  calculate  131I  activity  based  on  gland  size  and  24-hour  uptake.  There  are  no  data
comparing outcomes of fixed versus calculated activities in children. Calculated dosing seems
to help to ascertain that an adequate activity is given, and, as we know, activity > 150 μCi of
131I per gram of thyroid tissue results in a hypothyroidism rate of about 95%. It seems to be
especially important in this group to achieve the goal in a single RAI procedure. In the case of
failure, after 6 months the RAI therapy should be repeated for successful thyroid ablation. In
some  cases,  especially  in  small  children  or  in  the  case  of  non-compliance,  intravenous
radioactive iodine must be given. The activity should be calculated in the same way as for the
orally administered one.
Radioactive  iodine  is  excreted  in  saliva,  urine,  menstrual  blood,  and  stool.  Significant
radioactivity is retained for several days within the thyroid, so children and their families must
be informed about local radiation safety recommendations.
Acute side effects of RAI are rare, the most common being neck tenderness in the first week
following therapy. 
After RAI therapy thyroid hormones levels should be obtained every month. FT3/fT4 should
be  measured  because  TSH  levels  may  be  suppressed  for  several  months.  Typically,
hypothyroidism develops in 2–3 months, and then levothyroxine treatment should be started
[22–24].
Since RAI was introduced as a method of GD hyperthyroidism treatment over 70 years ago
there has been concern about its potential for producing malignancies, especially leukaemias
or thyroid cancer. 
As  we  know,  thyroid  cancer  and  thyroid  nodules  were  observed  in  children  exposed  to
radiation from nuclear fallouts, but these data do not apply directly when assessing risks of
RAI. The risk of thyroid cancer is higher in cases of exposure to low-level external radiation
and children exposed when younger than 10 years, similarly for boys and girls, but not in
cases of higher administered activities used during an RAI procedure. High doses resulted in a
lowering of risk because of cell killing [25, 26]. 
Unfortunately, the retrospective long-term observations in the paediatric group are limited due
to logistical difficulties in tracking patients. The data presented in Read’s paper [27] show that
in a cohort of 107 patients under the age of 20 years, treated with 131I between 1953 and 1973,
followed for 26 years, 98 of whom were followed for 36 years, there was not a single cancer
case. No malignancies were reported in Cohen’s paper within a shorter post-RAI follow-up
period of 2.4 years (range: 1 month–7.8 years) [28]. Nowadays a full ablation dose > 150 μCi
of 131I per gram of thyroid tissue is used in children, but long-term post-RAI observations in
paediatric groups are still required [16].
Thyroidectomy in children
Many paediatric  GD patients  eventually require  surgery as  the  definitive  treatment. Total
rather  than  partial  thyroidectomy  is  performed  to  avoid  the  risk  of  relapse.  Total
thyroidectomy is an effective treatment for paediatric GD with a high cure rate. According to
ATA/AACE guidelines, thyroidectomy is the preferred treatment for GD in young children (<
5 years),  in cases of large thyroid gland (> 80 g thyroid tissue), with significant Graves’
orbitopathy signs, and in cases of malignancy suspicion [16]. 
The  surgical  complication  rate  is  higher  in  children  than  in  adults.  The  total  number  of
complications is markedly higher in younger than in older children: 22% in the group 0–6
years old and 11% in the group 13–17 years old [29].
As  in  the  adult  population,  acute  complications  include  transient  hypocalcaemia,  wound
infection, and haematoma, while long-term complications include recurrent laryngeal nerve
(RLN) injury and permanent hypoparathyroidism.
First of all, it should be emphasised that complication rates of total thyroidectomy in children,
both  in  benign  thyroid  diseases  and  in  thyroid  cancer,  vary  depending  on  the  surgeon’s
experience.  Patients  treated  by  higher-volume  surgeons  have  significantly  fewer
complications than those treated by lower-volume surgeons. 
Many papers demonstrate significant reduction of complication rates in paediatric patients
receiving  thyroidectomy from high-volume  surgeons  (>  30  thyroidectomies  per  year)  as
compared to general paediatric surgeons. [29–31]. Tuggle made  cross-sectional analyses of
607 procedures (92% were thyroidectomies and 8% were parathyroidectomies) performed in
paediatric patients by high-volume surgeons (18%), paediatric surgeons (21%), and others
(61%).  In  multivariate  analyses surgeon  experience  was  an  independent  predictor  of
complications, length of hospitalisation, and finally total cost of treatment [32]. It must be
kept in mind while analysing the following data.
Hypocalcaemia is the most common complication after thyroidectomy in paediatric GD.
In  Cohen’s  group  of  30  GD  children,  there  were  six  cases  (20.0%)  of  permanent
hypoparathyroidism and  no cases  of  permanent  recurrent  laryngeal  nerve  injury [28].  As
reported  in  Hanba’s  paper,  nearly  20%  of  children  who  underwent  total  thyroidectomy
experienced postoperative hypocalcaemia and in 1.7% of them vocal cord paralysis was noted
[33]. 
The  reported  frequency  of  transient  hypocalcaemia  ranged  from  5.0  to  50.0%,  with  a
cumulative reported frequency of 22.2%. Transient hypocalcaemia, which normally resolves
within 6 months of thyroidectomy, can be distinguished from permanent hypoparathyroidism
when long-life calcium and active vitamin D supplementation is required. Normal parathyroid
function  1  year  after  surgery  was  described  in  most  children  who  underwent  a  total
thyroidectomy [34–36] with a cumulative reported permanent hypocalcaemia frequency of
2.5%.
Chen  et  al.  stated  that  diagnosis  of  GD  was  an  independent  risk  factor  of  developing
postoperative hypocalcaemia in children undergoing a thyroidectomy [37].
The second most frequently reported complication after TT in paediatric GD patients is RLN
injury.  Transient hoarseness may be caused by intubation,  the diagnosis of transient  RLN
injury in children can be made on the basis of clinical signs to avoid invasive diagnostic
procedures like laryngoscopy. However, laryngoscopy should be performed in each case of
postoperative  RLN  neuropraxia  if  the  patient  suffers  from long-lasting  deterioration  (>6
months) of the voice or other clinical signs of RLN injury do not resolve after speech therapy.
When pre- and postoperative laryngoscopy or a vocal cord function test were performed in the
paediatric patients who underwent thyroidectomy for GD, Machens et al. reported frequencies
of transient  and permanent  RLN injury of  3.4 and 0.0%, respectively [38].  In  22 mainly
retrospective cohort studies (1424 children and adolescents) analysed by Zaat, the cumulative
reported frequency of permanent RLN injury was 0.4% [34].
Other complications such as infections, haematoma, or keloid development were only rarely
reported.
Conclusions — how to make the right decision
The best treatment of GD in the paediatric population is still a debatable issue.  As a general
rule, ATD therapy is the primary treatment option. The decision of treatment discontinuation
is difficult  and requires careful consideration.  The choice of definitive therapy, if  needed,
depends on many important factors such as the child’s age, effectiveness of the first-line ATD
treatment,  presence of ATDs side effects, presence of large goitre or thyroid nodules, and
concomitant diseases.
For children younger than 5 years old long-term low-dose ATDs therapy, if well tolerated, is
the treatment of choice, with surgery in exceptional cases (e.g. ATD side effects). According
to  American  Thyroid  Association  and  American  Association  of  Clinical  Endocrinologists
(ATA/AACE) guidelines RAI should be avoided in this group.
In children aged 5–10 years ATDs are the first-line treatment and long-term, low-dose ATD
therapy is a possible treatment option. Definitive treatment is needed in the case of ATD side
effects. Thyroidectomy must be performed in the case of cancer risk or large goitre. RAI is
acceptable in this group if the calculated required dose is less than 10 mCi of 131I.
In children older than 10 years of age all of treatment methods can be used. If RAI is chosen,
the activity of 131I should be more than 150 μCi/g of thyroid tissue.
In the teenager group, preferably up to 15 years, RAI performed as an outpatient procedure
with activity of 131I more than 150 μCi/g of thyroid tissue is the treatment of choice.
In the case of necessary surgical treatment of GD in paediatric patients,  especially in the
youngest, thyroidectomy must always be performed by a high-volume surgeon. Only in such
cases  is  thyroidectomy  in  paediatric  patients  with  GD  a  safe  procedure  with  a  low
postoperative complication rate.
Pretreatment with ATDs aim to reach the euthyroidism before surgery is needed.
RAI  must  be  planned  and  performed  by  an  experienced  nuclear  medicine  specialist  in
accordance with current guidelines.
The benefits and risks of each therapy should be presented and explained to parents in the
case of small children or to adolescent patients. After definitive therapy in childhood, each
patient must be followed for life.
A multidisciplinary health-care team that includes an endocrinologist, an experienced thyroid
surgeon, and a nuclear medicine specialist would be optimal [16, 18, 19, 39, 40]. 
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